Comparative Pharmacology

Head-to-head clinical analysis: MARCAINE versus PARACAINE.

Peer-Reviewed Evidence

Differential Analysis

MARCAINE vs PARACAINE

Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.

MARCAINE

Local Anesthetic

Category C

PARACAINE

Local Anesthetic

Category C

Head-to-Head

Clinical Matrix

Mechanism of Action

Bupivacaine blocks sodium ion channels in nerve cell membranes, inhibiting the generation and propagation of action potentials, resulting in local anesthesia.

Local anesthetic that reversibly blocks sodium channels in neuronal membranes, inhibiting nerve impulse conduction.

Clinical Dosing

Local infiltration: 0.25-0.5% solution, up to 30 mL; peripheral nerve block: 0.25-0.5% solution, 30-40 mL; epidural: 0.5-0.75% solution, 15-30 mL. Maximum dose: 2 mg/kg (with epinephrine), 1.5 mg/kg (without epinephrine).

10-20 mg orally every 4-6 hours as needed; maximum 80 mg/day.

Direct Interaction

None Documented

Half-Life

Terminal elimination half-life: 2.5-4 hours in adults (longer in neonates and hepatic impairment; up to 8-12 hours). Clinically, accumulation occurs with continuous infusion or repeated doses.

Other Significant Interactions

Clinical Note

moderate

Proparacaine + Fluticasone propionate

"The risk or severity of adverse effects can be increased when Proparacaine is combined with Fluticasone propionate."

Clinical Note

moderate

Proparacaine + Clemastine

"The risk or severity of adverse effects can be increased when Proparacaine is combined with Clemastine."

Clinical Note

moderate

Proparacaine + Venlafaxine

"The risk or severity of adverse effects can be increased when Proparacaine is combined with Venlafaxine."

Clinical Note

moderate